Data Sheet 4: In Vitro Nanomedicine Delivery of KRASG12C Inhibitors

Annalisa Pia Abbinantefina published a PDF data sheet on 2026-03-17 describing a ferritin-derived nanomedicine platform for delivering KRASG12C inhibitors and degraders. The 59.9 KB document provides in vitro results from cellular models of KRAS-mutated non-small cell lung cancer and pancreatic ductal adenocarcinoma. It serves as a proof-of-concept for a tumor microenvironment-activated delivery system.

Use Cases

• Benchmarking nanocarrier drug delivery efficacy based on the described in vitro cellular models.
• Studying tumor microenvironment activation mechanisms based on the described MMP-2 and MMP-9 sensitivity.
• Comparing therapeutic outcomes of encapsulated vs. free drugs based on the described KRASG12C inhibitor and PROTAC degrader data.

Strengths

• Dataset is openly licensed under CC-BY-4.0.
• Documentation includes a detailed description of the nanomedicine platform and its experimental application.
• Data is recent, last updated on 2026-03-17.

Limitations

• Dataset is a 59.9 KB PDF, indicating a very limited data scope, likely a summary or supplementary figure.
• Row count and column-level data are unknown, requiring manual inspection after download.
• The data appears to be from in vitro cellular models, limiting direct physiological relevance.

Provenance

Source

Annalisa Pia Abbinantefina via figshare.

Collection Method

Likely contains experimental results from in vitro cellular models of KRAS-mutated cancers.

Freshness

Last updated 2026-03-17 13:08:13.